AccessibilityHelpAbout Us

Scribe Therapeutics(NASDAQ) SCTX

Market Cap$624.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+52%
5 YearN/A
1 YearN/A
1 Month+6%
$28.31
-14.21%
-4.69Today
Scribe Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 33.002026-09-18
Scribe Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.96%USD 29.742026-09-11
1 month+6.28%USD 31.052026-08-19
Since inception+52.42%USD 21.652026-07-24

Scribe Therapeutics Financials at a Glance

Market Cap

$624.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$26.17

Net Income (TTM)

-$37.15

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-5.67 (Low)

Price

$28.31

Volume

332,233.968

Open

$32.88

Previous Close

$33.00

Daily Range

$27.32 - $34.49

52-Week Range

$15.00 - $39.60

Estimated Earnings Date

Sep 2, 2026

SCTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scribe Therapeutics

Scribe Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing in vivo CRISPR-based genetic medicines. The company focuses on engineering proprietary technologies to target the genetic drivers of diseases, particularly atherosclerotic cardiovascular disease (ASCVD), with the goal of transitioning treatment from chronic care to preventative intervention.

Products and Services
  • CRISPR-based genetic medicines targeting genetic disease drivers
  • Innovative therapies aimed at atherosclerotic cardiovascular disease
  • Proprietary technologies for in vivo applications
Growth Outlook
  • Focus on preventative treatments positions Scribe for future market leadership
  • Strong pipeline development enhances potential for significant revenue growth
  • Increasing demand for genetic therapies supports long-term industry expansion
Financial Highlights
  • Market capitalization of approximately $552 million indicates strong investor interest
  • Stock price range between $17.31 and $39.6 reflects market confidence
  • Recent trading volume of 171,517 shares shows active market participation
Scribe Therapeutics is strategically positioned within the biotechnology sector, focusing on innovative solutions that address significant health challenges. The emphasis on CRISPR technology not only highlights the company's commitment to cutting-edge science but also its potential to transform treatment paradigms in healthcare. With a robust pipeline and a clear focus on preventative care, Scribe Therapeutics is poised for growth in a rapidly evolving market. The financial metrics indicate a solid foundation, with a notable market capitalization and active trading, suggesting a favorable environment for potential investors.
AI Generated • Aug 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

82

CEO

Benjamin L. Oakes, PhD

Website

www.scribetx.com

Headquarters

Alameda, CA 94501, US

SCTX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$624.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

18.93M

Volume

332.23K

Avg. Volume

284.48K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Scribe Therapeutics Performance Analysis

Scribe Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 27,413,000N/A
20252025-12-31USD 51,174,00086.7%
Scribe Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -2.72N/A
20252025-12-31USD -1.24-54.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.92

N/A

Gross Profit

$1.13

N/A

Gross Margin

59.07%

N/A

Market Cap

$624.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

82

N/A

Net Income

-$6.48

N/A

EBITDA

-$8.61

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$78.86

N/A

Total Debt

$43.27

N/A

Accounts Receivable

$1.11

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.10

N/A

Short Term Debt

$39.17

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$5.35

N/A

Operating Cash Flow

-$5.34

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,763.63+0.01%
^DJIDJI
$52,032.71+0.01%
^IXICNASDAQ
$27,092.05+0.02%
BTCBitcoin
$85,915.00+0.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.79+10.74%
GRMLGreenland Mines
$9.61+237.36%
INTCIntel
$121.38+11.77%
BITOProShares Trust - ProShares Bitcoin ETF
$11.55+5.77%

Questions About SCTX

What is the current price of Scribe Therapeutics?

Scribe Therapeutics is trading at $28.36 per share.

What is the 52-week range for Scribe Therapeutics?

Over the past 52 weeks, Scribe Therapeutics has traded between $15.00 and $39.60.

How much debt does Scribe Therapeutics have?

As of the most recent reporting period, Scribe Therapeutics reported total debt of $43.27M.

How much cash does Scribe Therapeutics have on hand?

Scribe Therapeutics reported $35.59M in cash and cash equivalents in its most recent financial results.

What is Scribe Therapeutics’s dividend yield?

Scribe Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services